Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:04:40·⟳ 抓取 04:05:19 +39s·⚡ 决策 10-13 04:07:42 +2m23s·14.6 天前
Syndax axatilimab治疗特发性肺纤维化MAXPIRe II期未达主要终点，公司终止该适应症开发
临床失败是真利空但属外围扩张适应症：已上市核心cGVHD业务与一线cGVHD关键试验不受影响，公司现金充足；消息在盘后发布后SNDX已下跌约15.5%并一度深跌46%后大幅拉回至14美元附近，显示逢低承接强、期权价值大部分已被消化，次日开盘追空风险收益差且面临4Q26正面催化。
📄 原文Investing.com↗ 原文
Syndax’s axatilimab fails primary endpoint in pulmonary fibrosis trial
S&P 500 little changed, Dow and Nasdaq mixed ahead of bank earnings, CPI this week NEW YORK - Syndax Pharmaceuticals (N…
不做 Syndax Pharmaceuticals（SNDX.US）
真实但外围的II期扩张适应症失败：核心cGVHD商业化与一线试验不受影响、现金充足；盘后已-15.5%且从-46%深V拉回，期权价值大部分出清，次日开盘追空风险收益差，事件本身也不构成任何做多理由，故双向不做。
不做 Incyte（INCY.US）
仅为axatilimab共同开发伙伴，单一非核心扩张适应症失败对其大盘市值无可交易重大性。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Syndax的axatilimab在IPF II期失败并终止该适应症，属于真实但非核心的管线挫折；盘后已重定价约15.5%、盘中一度-46%后被大幅买回，核心cGVHD业务与现金状况完好，做空剩余空间有限，结论为不做空、不做多。
消息传播链
- 公司宣布MAXPIRe II期IPF未达FVC主要终点并终止IPF开发，cGVHD试验不受影响；公司IR原稿URL未在搜索中直接返回，以通稿镜像核实
- 信号源转述公司声明，发布于美股收盘后约1小时
- 2026-10-12 16:05 ET市场反应futu盘后行情盘后从收盘16.55美元跌至最低9.01美元后拉回至13.99美元，约-15.5%，盘后成交约5.95万股，呈剧烈探底回升市场反应:SNDX盘后-15.5%，低点-45.6%后反弹
关键理由
- 利空真实但仅限IPF扩张期权：药物本身已获批上市且cGVHD试验不受影响，公司称现金约5.75亿美元可支撑至盈利
- 盘后已-15.5%且低点9.01美元被买回到13.99美元，说明期权价值大部分已出清，追空易遭遇技术反弹与4Q26一线cGVHD催化
主要风险
- 若卖方此前在模型中计入较高IPF peak sales，次日可能有进一步评级/目标价下调带来的下行
- 若一线cGVHD时间表或商业化出现任何负面信号，IPF失败会放大平台估值折让
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
公司已商业化、Niktimvo 2025全年净收入约1.52亿美元、现金约5.75亿美元可支撑至盈利，IPF只是扩张适应症，核心经营与偿付未受损
检索:axatilimab IPF peak sales materiality core cGVHD revenue cash runway 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
盘后深V回收显示逢低承接，且新诊断cGVHD关键数据预计2026年末/2028年初，构成临近的对冲性正面催化，追空风险高
检索:盘后低点9.01美元反弹至13.99美元 4Q26 1L cGVHD data catalyst
先例如何影响了这次决策
对本次决策的影响:先例不足直接支持不追空、不给SHORT ENTER，仅保留风险信号
方向:未取得可对齐首发锚的小型生物制药II期扩张适应症失败先例面板，不据此设定做空止盈幅度
涨幅量级:对齐样本不足；本轮唯一直接的重定价证据是SNDX自身盘后-15.5%且深V回收，提示剩余幅度不确定
形态:盘后一度-46%后被买回到-15.5%，类似非核心适应症失败常见的恐慌出清后修复形态，但无外部先例面板支撑
工具执行结果 · 成功 9 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`sndx axatilimab ipf phase 2 failure discontinuation | syndax axatilimab maxpire idiopathic pulmonary fibrosis primary endpoint | syndax incyte axatilimab pulmonary fibrosis trial 2`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 1,548 ms
豆包搜索结果（原始查询:Syndax axatilimab MAXPIRe Phase 2 idiopathic pulmonary fibrosis primary endpoint press release October 2026；API SearchType:web） - web_search 成功 doubao_search · 1,316 ms
豆包搜索结果（原始查询:SNDX axatilimab IPF failure analyst market cap cash runway 2026；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 425 ms
{ - direct_instrument_candidates 成功 stock_tools HTTP · 7 ms
{ - web_search 成功 doubao_search · 1,171 ms
豆包搜索结果（原始查询:Syndax MAXPIRe topline results October 12 2026 ir.syndax.com press release axatilimab IPF；API SearchType:web） - web_search 成功 doubao_search · 1,181 ms
豆包搜索结果（原始查询:axatilimab IPF peak sales estimate analyst Syndax MAXPIRe readout expected 2026 idiopathic pulmonary fibrosis opportunity；API SearchType:web） - validate_order 成功 stock_tools HTTP · 9 ms
{
原文全文
展开原文 · 2,098 字
S&P 500 little changed, Dow and Nasdaq mixed ahead of bank earnings, CPI this week
NEW YORK - Syndax Pharmaceuticals (NASDAQ:SNDX) announced Monday that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of annualized rate of decline in forced vital capacity, according to a press release statement.
The company said it does not plan further development of axatilimab in idiopathic pulmonary fibrosis based on the trial results. The drug was well tolerated with a safety profile comparable to placebo and no new safety signals were identified.
The MAXPIRe trial was a 26-week, randomized, double-blind, placebo-controlled study involving 145 patients enrolled across 62 sites in 14 countries. Patients were randomized 2:1 to receive axatilimab 0.3 mg/kg or placebo every two weeks.
Rates of treatment-emergent adverse events leading to treatment discontinuation were low in both arms. The most frequent adverse events in the axatilimab arm were consistent with previous studies. There were no treatment-related fatal adverse events in either arm.
Syndax stated the results from the MAXPIRe trial do not affect ongoing trials of axatilimab in other indications. The company said axatilimab continues to advance in multiple trials in chronic graft-versus-host disease, with results expected later this year and early 2028.
Axatilimab is a CSF-1R-blocking monoclonal antibody approved by the FDA for treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The drug is being studied in combination with standard-of-care therapies in patients with newly diagnosed chronic graft-versus-host disease in two ongoing clinical trials.
In 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic graft-versus-host disease and future indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Syndax Pharmaceuticals (NASDAQ:SNDX) announced Monday that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of annualized rate of decline in forced vital capacity, according to a press release statement.
The company said it does not plan further development of axatilimab in idiopathic pulmonary fibrosis based on the trial results. The drug was well tolerated with a safety profile comparable to placebo and no new safety signals were identified.
The MAXPIRe trial was a 26-week, randomized, double-blind, placebo-controlled study involving 145 patients enrolled across 62 sites in 14 countries. Patients were randomized 2:1 to receive axatilimab 0.3 mg/kg or placebo every two weeks.
Rates of treatment-emergent adverse events leading to treatment discontinuation were low in both arms. The most frequent adverse events in the axatilimab arm were consistent with previous studies. There were no treatment-related fatal adverse events in either arm.
Syndax stated the results from the MAXPIRe trial do not affect ongoing trials of axatilimab in other indications. The company said axatilimab continues to advance in multiple trials in chronic graft-versus-host disease, with results expected later this year and early 2028.
Axatilimab is a CSF-1R-blocking monoclonal antibody approved by the FDA for treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The drug is being studied in combination with standard-of-care therapies in patients with newly diagnosed chronic graft-versus-host disease in two ongoing clinical trials.
In 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic graft-versus-host disease and future indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2c64530087· 2026-10-13 04:07 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前